Literature DB >> 12106609

Membrane heme as a host factor in reducing effectiveness of dihydroartemisinin.

Phantip Vattanaviboon1, Noppadol Siritanaratkul, Jidapa Ketpirune, Prapon Wilairat, Yongyuth Yuthavong.   

Abstract

Plasmodium falciparum infecting alpha-thalassemic erythrocytes are resistant to artemisinin and its derivatives. Binding of the drug to hemoglobin H resulting in drug inactivation was previously demonstrated. We now show that an additional host factor, membrane heme, significantly accounted for decreased antimalarial activity of artemisinin. The antimalarial activity of dihydroartemisinin in the presence of normal and thalassemic erythrocyte membranes showed a correlation with the heme content of the membrane (r(2)=0.466, P<0.01). The correlation was more clearly seen when the drug effectiveness was correlated with the heme content of alpha-thalassemic membrane (r(2)=0.636, P<0.01). However, the drug effectiveness showed no correlation to ferrozine-reactive (free or non-heme) iron content (r(2)=0.0001, P>0.05). alpha-Thalassemic erythrocytes contained higher amounts of membrane heme (11.04+/-8.96 nmol/mg membrane protein) than those from normal and beta-thalassemia/HbE erythrocytes (2.68+/-1.28 and 3.98+/-3.98 nmol/mg membrane protein, respectively, P<0.01). Loss of drug effectiveness was also correlated with increment of heme content in membrane prepared from normal erythrocytes treated with phenylhydrazine. It is concluded that heme in both normal and thalassemic erythrocyte membranes is an important factor in drug inactivation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12106609     DOI: 10.1016/s0006-2952(02)01060-2

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

Review 1.  Plasmodium drug targets outside the genetic control of the parasite.

Authors:  David J Sullivan
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

2.  Artemisone uptake in Plasmodium falciparum-infected erythrocytes.

Authors:  Sophie Pooley; Farrah A Fatih; Sanjeev Krishna; Michael Gerisch; Richard K Haynes; Ho-Ning Wong; Henry M Staines
Journal:  Antimicrob Agents Chemother       Date:  2010-12-06       Impact factor: 5.191

3.  Artemisinin Therapy for Malaria in Hemoglobinopathies: A Systematic Review.

Authors:  Sri Riyati Sugiarto; Brioni R Moore; Julie Makani; Timothy M E Davis
Journal:  Clin Infect Dis       Date:  2018-02-10       Impact factor: 9.079

4.  Artemisinin effectiveness in erythrocytes is reduced by heme and heme-containing proteins.

Authors:  Napawan Ponmee; Tatsanee Chuchue; Prapon Wilairat; Yongyuth Yuthavong; Sumalee Kamchonwongpaisan
Journal:  Biochem Pharmacol       Date:  2007-03-15       Impact factor: 5.858

5.  Disposition of artesunate and dihydroartemisinin after administration of artesunate suppositories in children from Papua New Guinea with uncomplicated malaria.

Authors:  Harin A Karunajeewa; Kenneth F Ilett; Kitiya Dufall; Adedayo Kemiki; Moses Bockarie; Michael P Alpers; P Hugh Barrett; Paolo Vicini; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

6.  Two distinct and competitive pathways confer the cellcidal actions of artemisinins.

Authors:  Chen Sun; Jian Li; Yu Cao; Gongbo Long; Bing Zhou
Journal:  Microb Cell       Date:  2015-01-02

Review 7.  The molecular and cellular action properties of artemisinins: what has yeast told us?

Authors:  Chen Sun; Bing Zhou
Journal:  Microb Cell       Date:  2016-04-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.